Sparano JA et al. (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: 1663–1671
Adding adjuvant taxane therapy to an anthracycline-containing chemotherapy regimen has been shown to reduce the risks of disease recurrence and death in women with operable breast cancer. Sparano and co-workers investigated the optimum adjuvant taxane agent and administration schedule in this setting and found that weekly adjuvant paclitaxel therapy after doxorubicin and cyclophosphamide chemotherapy improves both disease-free and overall survival in women with breast cancer.
This study enrolled 4,950 women with operable, histologically confirmed axillarylymph-node-positive or high-risk, axillary-lymph-node-negative breast cancer. All participants were assigned to receive doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) once every 3 weeks for 4 cycles and were randomly assigned to receive weekly or 3-weekly paclitaxel (80 mg/m2 for 12 doses or 175 mg/m2 for 4 doses, respectively) or docetaxel (35 mg/m2 for 12 doses or 100 mg/m2 for 4 doses, respectively).
Patients who received weekly paclitaxel had significantly better disease-free and overall survival than those who received the current standard therapy of 3-weekly paclitaxel (hazard ratio [HR] 1.27, P = 0.006 and HR 1.32, P = 0.01, respectively). The survival benefit conferred by weekly paclitaxel was maintained in patients with HER2-negative disease, regardless of hormone-receptor status. Docetaxel administered once every 3 weeks improved disease-free survival, but not overall survival, compared with 3-weekly paclitaxel (HR 1.23, P = 0.02 and HR 1.13, P = 0.25, respectively) but did not significantly improve either survival outcome compared with standard therapy when administered weekly. The weekly paclitaxel group had a significantly higher incidence of moderate to severe neuropathy than any other treatment group (P <0.001 for all comparisons).
Rights and permissions
About this article
Cite this article
Weekly adjuvant paclitaxel improves survival after standard chemotherapy in breast cancer. Nat Rev Clin Oncol 5, 498 (2008). https://doi.org/10.1038/ncponc1171
Issue Date:
DOI: https://doi.org/10.1038/ncponc1171